Biotechnology company Celgene ( CELG) late Monday said that it would miss Street estimates for 2007 and that revenue rose 60% from a year ago.

The company forecasts 2007 sales of $1.3 billion and adjusted EPS of a dollar. Analysts at Thomson First Call are looking for 2007 revenue of $1.38 billion and adjusted earnings of $1.09.

Celgene said that 2006 revenue increased to $890 million on strong sales of Revlimid that ranged from $315 million to $320 million for 2006. Thalomid sales ranged from $425 million to $430 million. Adjusted earnings per share nearly tripled in 2006.

Earlier this week, the Summit, N.J.-based pharmaceutical companynamed its chief executive, Sol Barer, to an added chairman's post.

Shares of Celgene were recently off 3%, or $1.72, to $55.58 in after-hours trading.

Celgene will report its official 2006 financial results on Feb. 1.

More from Stocks

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

Here's Why Snap Shares Are Climbing Monday

Here's Why Snap Shares Are Climbing Monday

Dropbox Soars in Third-Straight Record-Setting Session

Dropbox Soars in Third-Straight Record-Setting Session

Tesla's Elon Musk Just Told Short-Sellers They're Toast

Tesla's Elon Musk Just Told Short-Sellers They're Toast

Jim Cramer: Centene Is in All the Big Medicare Markets

Jim Cramer: Centene Is in All the Big Medicare Markets